Elanco Animal Health Inc
Elanco Animal Health Inc (ELAN) is a global animal health company that develops and sells pharmaceuticals, vaccines and parasiticides for companion animals and livestock. Investors should know its business is split between higher-margin companion-animal products (pets) and larger-volume livestock offerings, giving exposure to both consumer-driven and agricultural demand cycles. Growth has been shaped by product launches and acquisitions, while margins and cash flow can be influenced by integration costs, commodity-linked livestock markets and regulatory approvals. Key risks include competition, pricing pressure, and the need for ongoing R&D investment. The company’s operations are global, so currency and regional regulatory environments matter. This summary is for general educational purposes only and is not personal financial advice; values can rise and fall and investors should consider their risk tolerance and seek independent advice where needed.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Elanco's stock with a target price of $22.50, indicating potential growth.
Financial Health
Elanco is generating solid revenue and cash flow, with healthy profit margins indicating strong overall performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ELAN
Next-Gen Proteins
Looking to invest in the future of food? This carefully selected group of stocks represents companies solving our global protein challenges. From plant-based alternatives to agricultural innovation, these stocks have been thoughtfully chosen by our analysts for their potential in this growing market.
Published: June 17, 2025
Explore BasketPets Are Family
The emotional bond with our furry companions has created a powerful, recession-resistant market. These carefully selected companies provide essential veterinary care, nutrition, and wellness services that pet owners prioritize regardless of economic conditions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Companion-Animal Momentum
Companion products often command higher margins and steady demand as pet ownership rises, though results can vary and competition is strong.
Global Livestock Exposure
A large livestock portfolio gives exposure to agricultural cycles and emerging-market protein demand, but commodity swings and regulatory factors add volatility.
Pipeline and M&A
R&D and strategic acquisitions can boost future revenues, yet integration costs and approval risks mean outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
